.jpeg)
{{ variable.name }}
Indications:
Treatment of endometriosis.
Usage and dosage:
Take orally, one tablet per day, without interruption, preferably at the same time every day, with water when necessary. This product can be taken after meals or on an empty stomach. The tablets must be taken continuously, regardless of whether vaginal bleeding occurs. If you finish taking one box, start taking the next box without interruption. You can start treatment with this product on any day of the menstrual cycle.
Adverse reactions:
The most common side effects are headache, breast discomfort, including breast swelling and breast pain. Adverse effects such as irregular bleeding are more common during the first few months of treatment with Visanin and gradually disappear as treatment continues.
There are no serious life-threatening side effects. Common side effects are amenorrhea, irregular bleeding, headache, chest discomfort, depression and acne, etc., and can be recovered after stopping the medication.
Contraindications:
Contraindicated for patients allergic to this product
Dienogest tablets should not be used under the conditions listed below, some of which are derived from information on other progestin preparations. If any of the following conditions occur while using dienogest tablets, you must stop taking it immediately.
New active venous thromboembolic disease
Current or past arterial and cardiovascular diseases (such as myocardial infarction, cerebrovascular accident, ischemic heart disease)
Diabetes potential for vascular lesions.
Rare cases of benign liver tumors and even rarer cases of malignant liver tumors have been reported in users of hormonal drugs (such as those contained in dienogest tablets). In individual cases, these tumors can cause life-threatening intra-abdominal bleeding. When women taking dienogest tablets experience severe upper abdominal pain, liver enlargement or signs of intra-abdominal bleeding, the presence of liver swelling and pain needs to be considered in syndrome differentiation.
Osteoporosis
Precautions:
Severe uterine bleeding: For example, in women with adenomyosis or uterine leiomyomas, uterine bleeding may be worsened while using dienogest tablets. If the bleeding is large or continuous, it may lead to anemia (severe anemia occurs in some cases). In the event of anemia, discontinuation of dienogest tablets should be considered.
Changes in bleeding patterns: Most patients treated with dienogest tablets experienced changes in menstrual bleeding patterns.
Circulatory disorders: Based on epidemiological studies, there is little evidence of an association between single progestin preparations and an increased risk of myocardial infarction or cerebral thromboembolism. However, the risk of cardiovascular and cerebrovascular events is significantly associated with increasing age, hypertension, and smoking. In women with high blood pressure, progestin-only medications may slightly increase the risk of stroke.
Some studies have shown that the use of single progestin drugs combined with venous thromboembolism (deep vein thrombosis, pulmonary embolism) risk is slightly increased, but the increase is not statistically significant. It is generally believed that risk factors for venous thromboembolism (VTE) include: a personal or family history of a sibling or parent who developed VTE at a relatively young age, age, obesity, long-term immobilization, major surgery, or severe trauma. In the case of long-term immobilization, it is best to stop using dienogest tablets (if elective surgery is to be performed, stop taking the medicine at least 4 weeks in advance), and resume use after 2 weeks of complete reactivation.
The increased risk of thromboembolism during the puerperium must be considered.
If symptoms of arterial or venous thrombosis are present or suspected, treatment should be stopped immediately
Tumor: A meta-analysis of 54 epidemiological studies reported that women currently using oral contraceptives (OCs) (mainly estrogen and progestin combination preparations) have a slightly increased relative risk of breast cancer.
Storage:
No more than 25℃, keep tightly sealed in the original packaging.
Mechanism of action:
Dienogest is a 19-nortestosterone derivative that does not have androgenic activity, but has anti-androgenic activity. Its activity is about one-third that of cyproterone acetate. The affinity of dienogest for binding to the progesterone receptor in the human uterus is only 10% of that of progesterone. Although its affinity for the progesterone receptor is low, it has a potent progesterone effect in the body. Dienogest has no obvious androgenic, mineralocorticoid, or glucocorticoid activity in the body.
Dienogest plays a role in endometriosis by reducing the endogenous production of estradiol, thereby inhibiting the stimulating effect of estradiol on normal and ectopic endometrium. When administered continuously, dienogest induces an endocrine environment of low estrogen and high progesterone, causing decidualization of endometrial tissue, thereby shrinking endometriosis lesions.